Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24312631 | 0.92 | TMPRSS2 (0.50) | TMPRSS2HSPA2 | |
| SCHEMBL25383763 | 0.90 | TMPRSS2 (0.53) | TMPRSS2RIPK1 | |
| SCHEMBL25381965 | 0.89 | TMPRSS2 (0.47) | TMPRSS2RIPK1 | |
| SCHEMBL24312592 | 0.88 | TMPRSS2 (0.46) | TMPRSS2RIPK1 | |
| SCHEMBL24313286 | 0.88 | TMPRSS2 (0.50) | TMPRSS2RIPK1 | |
| SCHEMBL25381315 | 0.87 | TMPRSS2 (0.46) | TMPRSS2RIPK1 | |
| SCHEMBL27121048 | 0.87 | TMPRSS2 (0.51) | TMPRSS2RIPK1 | |
| SCHEMBL25608866 | 0.87 | TMPRSS2 (0.45) | TMPRSS2RIPK1 | |
| SCHEMBL25607765 | 0.87 | TMPRSS2 (0.45) | TMPRSS2RIPK1 | |
| SCHEMBL25909400 | 0.87 | TMPRSS2 (0.47) | TMPRSS2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317754-A1 | METHODS AND MODIFIED NUCLEOSIDES FOR TREATING CORONAVIRUS INFECTIONS | SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-09-26 | — | — | US | disclosed |
| WO-2022142477-A1 | METHODS AND MODIFIED NUCLEOSIDES FOR TREATING CORONAVIRUS INFECTIONS | SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317754-A1 | METHODS AND MODIFIED NUCLEOSIDES FOR TREATING CORONAVIRUS INFECTIONS | PNP, MTAP, NSUN2 | TMPRSS2 69/4885ALDH1A1 1975/4885HSPA2 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.